As part of the CSL Group, Seqirus is committed to ensuring the transparency and public accessibility of information related to our global clinical research activities. This information enhances scientific exchange, and helps people to make informed decisions about potential influenza vaccine options as well as potential participation in clinical trials. Seqirus makes every effort to comply with national and international standards relevant to clinical trial disclosure and data.
To this end, we are committed to:
- The prospective registration on a publicly available trial registry of all Seqirus-sponsored clinical trials and applicable observational/non-interventional studies (NIS); and
- The reporting of results of completed Seqirus-sponsored clinical trials and applicable observational studies/NIS on a results database or equivalent website, according to regulatory requirements. Results are made publically available, regardless of the outcome.